Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, H2 2016

  • ID: 4030244
  • Report
  • 58 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Complexa Inc
  • GlaxoSmithKline Plc
  • Retrophin Inc
  • Shire Plc
  • MORE
Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, H2 2016

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Focal Segmental Glomerulosclerosis - Pipeline Review, H2 2016, provides an overview of the Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline landscape.

Focal Segmental glomerulosclerosis is a rare disease that attacks the kidney’s filtering units (glomeruli) causing serious scarring which leads to permanent kidney damage and even failure. Symptoms include proteinuria, edema, high cholesterol, high blood pressure and poor appetite. Risk factors include infection, obesity, sickle cell disease and reflux nephropathy. Treatment includes antibiotics, vitamin D supplements, and immunosuppressive drugs.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Focal Segmental Glomerulosclerosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Focal Segmental Glomerulosclerosis (FSGS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Focal Segmental Glomerulosclerosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Complexa Inc
  • GlaxoSmithKline Plc
  • Retrophin Inc
  • Shire Plc
  • MORE
Introduction

Focal Segmental Glomerulosclerosis (FSGS) Overview

Therapeutics Development

Pipeline Products for Focal Segmental Glomerulosclerosis (FSGS) - Overview

Pipeline Products for Focal Segmental Glomerulosclerosis (FSGS) - Comparative Analysis

Focal Segmental Glomerulosclerosis (FSGS) - Therapeutics under Development by Companies

Focal Segmental Glomerulosclerosis (FSGS) - Therapeutics under Investigation by Universities/Institutes

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Focal Segmental Glomerulosclerosis (FSGS) - Products under Development by Companies

Focal Segmental Glomerulosclerosis (FSGS) - Products under Investigation by Universities/Institutes

Focal Segmental Glomerulosclerosis (FSGS) - Companies Involved in Therapeutics Development

Complexa Inc

Dimerix Bioscience Pty Ltd

GlaxoSmithKline Plc

Retrophin Inc

Shire Plc

Variant Pharmaceuticals Inc

Focal Segmental Glomerulosclerosis (FSGS) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(irbesartan + propagermanium) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CXA-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

losmapimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHP-627 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sparsentan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-5484 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAR-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Focal Segmental Glomerulosclerosis (FSGS) - Dormant Projects

Focal Segmental Glomerulosclerosis (FSGS) - Discontinued Products

Focal Segmental Glomerulosclerosis (FSGS) - Product Development Milestones

Featured News & Press Releases

Nov 30, 2016: World Renowned Experts Join Variant Pharmaceuticals' Scientific Advisory Board

Nov 21, 2016: Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016

Nov 19, 2016: Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016

Oct 21, 2016: Retrophin to Present Additional Data from Phase 2 DUET Study of Sparsentan in Late-Breaking Oral Session at ASN Kidney Week 2016

Sep 07, 2016: Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis

Aug 01, 2016: Dimerix announces outcomes of DMX-200 pre-IND meeting with the FDA

Mar 30, 2016: Retrophin Completes Enrollment of Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis

Dec 14, 2015: Dimerix receives Orphan Designation for its lead drug candidate targeting patients with chronic kidney disease

Nov 16, 2015: Retrophin Receives European Orphan Drug Designation for Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis

Jan 09, 2015: Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan

Feb 25, 2013: Ligand Receives $1.4m Milestone Payment From Retrophin

Jan 09, 2013: Ligand Receives Equity Milestone Payment From Retrophin

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS), H2 2016

Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS) - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Complexa Inc, H2 2016

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by GlaxoSmithKline Plc, H2 2016

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Retrophin Inc, H2 2016

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Shire Plc, H2 2016

Focal Segmental Glomerulosclerosis (FSGS) - Pipeline by Variant Pharmaceuticals Inc, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Focal Segmental Glomerulosclerosis (FSGS) - Dormant Projects, H2 2016

Focal Segmental Glomerulosclerosis (FSGS) - Discontinued Products, H2 2016

List of Figures:

Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS), H2 2016

Number of Products under Development for Focal Segmental Glomerulosclerosis (FSGS) - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Complexa Inc
  • Dimerix Bioscience Pty Ltd
  • GlaxoSmithKline Plc
  • Retrophin Inc
  • Shire Plc
  • Variant Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll